Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists investigate why breast cancer beats treatments

NCT ID NCT06274515

Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 5 times

Summary

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells that allow them to survive treatment, which could lead to better therapies in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General Inclusion Criteria: * Willingness to undergo a procedure to obtain tumor tissue (e.g. biopsy) and blood draw * Diagnosis of HER2+, HR+ (for cohort R1) or triple negative breast cancer (for cohort T1) as per local assessment * Availability of an archival tumor tissue (most recent pre-treatment tumor tissue is preferred) * Unequivocally growing tumor lesion (progressive lesion) that is accessible for resection, excision or core needle biopsy * Discontinuation of prior anti-cancer treatment outlined below should not be longer than 4 weeks from participation in this study Inclusion criteria for participants in the cohorts studying acquired resistance * Participant had undergone regular monitoring for disease progression as per local practice (preferably every 3-6 months) while on most recent breast cancer therapy * Accessible tumor lesion that newly appeared or a lesion that started to regrow while the participant was at least 6 months on therapy Inclusion criteria for participants in the cohort studying primary resistance * Accessible tumor lesion that continued to increase in size or a newly appearing lesion (as confirmed by routine tumor assessment) while treated for at least 4 weeks but less than 6 months on therapy Exclusion Criteria: * Any risks factors that increase the risk of complications associated with the procedure to obtain tumor tissue (e.g. bleeding disorders) * Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study * Participant has started treatment with subsequent anti-cancer therapy * Participants whose progressive tumor lesion that is targeted for biopsy/resection is in the bone * Discontinuation of treatment was due to a reason other than disease progression

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Delta (Campus Rumbeke)

    RECRUITING

    Roeselare, 8800, Belgium

  • AZ KLINA

    RECRUITING

    Brasschaat, 2930, Belgium

  • Aalborg Universitetshospital

    RECRUITING

    Aalborg, 9000, Denmark

  • Azienda Ospedaliero - Universitaria di Modena Policlinico

    RECRUITING

    Modena, Emilia-Romagna, 41110, Italy

  • Basingstoke and North Hampshire Hospital

    RECRUITING

    Basingstoke, RG24 9NA, United Kingdom

  • CHU de Liège (Sart Tilman)

    RECRUITING

    Liège, 4000, Belgium

  • Christie Hospital NHS Trust

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    RECRUITING

    Rome, Lazio, 00168, Italy

  • HM Sanchinarro ? CIOCC

    RECRUITING

    Madrid, 28050, Spain

  • Helsinki University Central Hospital

    RECRUITING

    Helsinki, 00029, Finland

  • Hospital Clínico Universitario de Valencia

    RECRUITING

    Valencia, 46010, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, 41013, Spain

  • I.R.S.T Srl IRCCS

    RECRUITING

    Meldola, Emilia-Romagna, 47014, Italy

  • Imperial College Healthcare NHS Trust

    RECRUITING

    London, W6 8RF, United Kingdom

  • Institut Jules Bordet

    RECRUITING

    Anderlecht, 1070, Belgium

  • Irccs Istituto Europeo Di Oncologia (IEO)

    RECRUITING

    Milan, Lombardy, 20141, Italy

  • Irccs Istituto Nazionale Dei Tumori (Int)

    RECRUITING

    Milan, Lombardy, 20133, Italy

  • KEM/Evang. Kliniken Essen Mitte gGmbH

    RECRUITING

    Essen, 45136, Germany

  • Oslo university hospital Radiumhospitalet

    WITHDRAWN

    Oslo, 0424, Norway

  • Ospedale San Raffaele S.r.l. - PPDS

    RECRUITING

    Milan, Lombardy, 20132, Italy

  • RCCS - Centro di Riferimento

    RECRUITING

    Aviano (PN), Friuli Venezia Giulia, 33081, Italy

  • Sjællands Universitetshospital, Næstved

    RECRUITING

    Næstved, 4700, Denmark

  • St. Elisabeth Krankenhaus Köln GmbH

    RECRUITING

    Cologne, 50935, Germany

  • Tampere University Hospital

    RECRUITING

    Tampere, 33520, Finland

  • Universitätsfrauenklinik Ulm

    RECRUITING

    Ulm, 89075, Germany

  • Universitätsklinikum Mannheim

    RECRUITING

    Mannheim, 68167, Germany

  • ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG

    RECRUITING

    Karlsruhe, 76135, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.